Labeling and Linkage Agents for Immunoassays and Gene Probes

Table of Contents

• INTRODUCTION
  • OBJECTIVES AND GOAL OF THE STUDY
  • REASONS FOR DOING THE STUDY
  • SCOPE OF THE STUDY
  • TARGETED AUDIENCE
  • METHODOLOGY
  • CREDENTIALS OF ANALYSTS
  • RELATED BCC REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER
• SUMMARY
  • Summary Table: MARKETS FOR LABELS AND PROBES BY APPLICATION AREA, THROUGH 2010 ($ MILLIONS)
  • Summary Figure: MARKETS FOR LABELS AND PROBES BY APPLICATION AREA, 2003-2010 ($ MILLIONS)
• TECHNOLOGY OVERVIEW
  • IMMUNOASSAY TECHNOLOGY
    • QUALITATIVE AND QUANTITATIVE IMMUNOASSAYS
    • APPLICATION FIELDS FOR IMMUNOASSAY TECHNIQUES
    • COMPARISON OF IMMUNOASSAYS WITH CONVENTIONAL METHODS
      • High Sensitivity
      • High Selectivity
      • Speed
      • Cost Factors
      • Easier Cleanup Process
      • Efficiency
      • Some Drawbacks
    • ADVANCES IN IMMUNOASSAY TECHNOLOGY
    • METHODS OF IMMUNOASSAYS
      • Immunoprecipitation
      • Particle Immunoassays
      • Radioimmunoassay (RIA)
        • Immuno Radiometric Assays
      • Immunonephelometry and Fluorescent Immunoassay (FIA)
        • Immunonephelometry
        • Fluorescent Immunoassay (FIA)
        • Fluorescence Polarization (FP): Variation of FIA
        • Comparative Performance between EIA and FIA
      • Enzyme Immunoassay (EIA) / Enzyme Linked Immunosorbent Assays (ELISA)
      • Chemiluminecent Assay (CLIA)
      • Examples of Other Immunoassays
    • IMMUNOASSAY TECHNIQUES
      • Monoclonal-Polyclonal (MoAb-PoAb) Sandwich Immunoassay
      • Competitive Inhibition Immunoassay
      • Antigen-Down Immunoassay
      • Rapid Immunoassays
  • GENE PROBE TECHNOLOGY (NUCLEIC ACID ASSAYS)
    • CONSTRUCTION OF PROBES
    • PROBE LABELING
    • NONRADIOACTIVE LABELING OF GENE PROBES
    • IMMUNOASSAY-DNA PROBE HYBRID ASSAYS
    • DETECTION IN FOODS
    • CHIP-BASED NUCLEIC ACID ASSAY
    • REPORTER TECHNOLOGY
      • Chemiluminescent Assays
  • EXAMPLES OF TECHNOLOGY DEVELOPMENTS
    • DETECTION OF DNA HYBRIDIZATION WITH IMPEDANCE AMPLIFYING LABELS
    • QUANTITATIVE FLUORESCENT IMMUNOASSAY OF ANTIBODIES
    • COLORIMETRIC POLYMERASE ASSAY
    • DEVELOPMENT AND PROLIFERATION OF RADIOIMMUNOASSAY TECHNOLOGY
  • HISTORIC MILESTONES IN TECHNOLOGY DEVELOPMENT
    • IMMUNOASSAYS
  • Table 1 IMMUNOASSAYS: HISTORICAL TIMELINE
  • Table 1 (CONTINUED)
    • GENE PROBES
  • Table 2 GENE PROBES: HISTORICAL TIMELINE
    • RADIOACTIVE COMPOUNDS
  • Table 3 RADIOACTIVE COMPOUNDS: HISTORICAL TIMELINE
  • Table 3 (CONTINUED)
• OVERVIEW OF PROBES AND RELATED CHEMICALS
  • RADIOACTIVE COMPOUNDS
  • ENZYMES/ENZYME SUBSTRATES
  • FLUORESCEIN COMPOUNDS
  • CHEMILUMINESCENCE COMPOUNDS
  • GENE PROBES
    • IMMUNOASSAY-DNA PROBE HYBRID ASSAYS
    • FOOD TESTING
  • EXAMPLES OF RADIOACTIVE COMPOUNDS AND THEIR APPLICATIONS
  • Table 4 COMMONLY USED RADIOACTIVE ISOTOPES
  • Table 5 RADIONUCLIDES FOR DIAGNOSTIC IMAGING
    • 99mTc
    • Positron Emitters
  • Table 6 RADIONUCLIDES: POSITRON EMITTERS
  • Table 7 USE OF RADIOACTIVE PROBES: THYROID IMAGING
  • Table 7 (CONTINUED)
  • Table 8 USE OF RADIOACTIVE PROBES: AUTORADIOGRAPHY
  • Table 9 USE OF RADIOACTIVE PROBES: IN DIAGNOSIS AND THERAPY
  • Table 10 USE OF RADIOACTIVE PROBES: RADIOCARDIOGRAPHY
  • Table 11 USE OF RADIOACTIVE PROBES: TUMOR IMAGING
  • Table 12 USE OF RADIOACTIVE PROBES: CANCER TREATMENT
  • Table 13 USE OF RADIOACTIVE PROBES: DETERMINATION OF BLOOD CELL SURVIVAL TIME
  • Table 14 USE OF RADIOACTIVE PROBES: DETERMINATION OF CIRCULATION RED CELL MASS/PLASMA VOLUME
  • Table 15 USE OF RADIOACTIVE PROBES: DETERMINATION OF BLOOD FLOW
  • Table 16 USE OF RADIOACTIVE PROBES: STOMACH IMAGING
  • Table 17 USE OF RADIOACTIVE PROBES: EXCRETION STUDY
  • Table 18 USE OF RADIOACTIVE PROBES: TREATMENT OF LEUKEMIAS
  • Table 19 USE OF RADIOACTIVE PROBES: STUDY OF GASTROINTESTINAL PROTEIN LOSS
  • Table 20 USE OF RADIOACTIVE PROBES: SCANNING LUNGS/BRAIN
  • Table 21 USE OF RADIOACTIVE PROBES: MYOCARDIAL STUDIES
  • Table 22 USE OF RADIOACTIVE PROBES: HEART IMAGING
  • Table 22 (CONTINUED)
  • Table 23 USE OF RADIOACTIVE PROBES: BRAIN IMAGING
  • Table 24 USE OF RADIOACTIVE PROBES: BRAIN PERFUSION IMAGING
  • Table 25 USE OF RADIOACTIVE PROBES: BONE IMAGING
  • Table 26 USE OF RADIOACTIVE PROBES: LUNG IMAGING
  • Table 26 (CONTINUED)
    • Hepatobiliary Imaging
    • Reticuloendothelial System
  • Table 27 USE OF RADIOACTIVE PROBES: RENAL IMAGING
  • Table 28 USE OF RADIOACTIVE PROBES: MALIGNANT AND INFLAMMATORY REGIONS
    • Experimental Agents
    • ENZYME PROBES
  • Table 29 COMMONLY USED TYPE OF EIAS
    • A capture EIA is designed to detect a specific type of antibody, such as IgG or IgM.
  • Table 30 COMMONLY USED ENZYMES IN EIAS
  • Table 31 APPLICATIONS OF ENZYMES IN IMMUNOASSAY
  • Table 31 (CONTINUED)
  • Table 31 (CONTINUED)
    • FLUORESCENCE COMPOUNDS
  • Table 32 COMMONLY USED FLUOROPHORES IN FIA
  • Table 33 FLUOROPHORES AND THEIR APPLICATIONS
  • Table 33 (CONTINUED)
  • Table 33 (CONTINUED)
    • CHEMILUMINESCENT COMPOUNDS
  • Table 34 COMMONLY USED CHEMILUMINESCENT COMPOUNDS
• MARKETS FOR PROBES BY APPLICATION SECTORS
  • GLOBAL MARKET FOR PROBES
  • Table 35 GLOBAL MARKET FOR PROBES IN IMMUNOASSAYS BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
  • Table 36 GLOBAL MARKET BY MATERIALS FOR PROBES IN IMMUNOASSAYS, THROUGH 2010 ($ MILLIONS)
  • Figure 1 GLOBAL MARKET BY MATERIALS FOR PROBES IN IMMUNOASSAYS, 2003-2010 ($ MILLIONS)
  • Table 37 REGIONAL SHARE OF THE MARKET FOR PROBES IN IMMUNOASSAYS, THROUGH 2010 ($ MILLIONS)
  • Figure 2 REGIONAL SHARE OF MARKETS FOR PROBES IN IMMUNOASSAYS, 2005 (%)
    • IN VITRO DIAGNOSTICS
  • Table 38 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
  • Figure 3 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS BY APPLICATION SECTORS, 2003-2010 ($ MILLIONS)
  • Table 39 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS BY REGION, THROUGH 2010 ($ MILLIONS)
  • Table 40 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS BY REAGENTS, THROUGH 2010 ($ MILLIONS)
    • Medical Labs
  • Table 41 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS MEDICAL LABS, THROUGH 2010 ($ MILLIONS)
    • Types of Tests
    • Hospital Testing
  • Table 42 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS HOSPITAL TESTING, THROUGH 2010 ($ MILLIONS)
    • Types of Tests
    • Doctors Offices
  • Table 43 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS DOCTORS OFFICE, THROUGH 2010 ($ MILLIONS)
    • Home Testing
  • Table 44 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS HOME TESTING, THROUGH 2010 ($ MILLIONS)
    • Typical Tests
    • Likely Future Trends in the Probes Markets for IVD Sector
    • IN VIVO DIAGNOSTICS
  • Table 45 GLOBAL MARKET FOR PROBES FOR IN VIVO DIAGNOSTICS, THROUGH 2010 ($ MILLIONS)
  • Figure 4 GLOBAL MARKET FOR PROBES FOR IN VIVO DIAGNOSTICS, 2003-2010 ($ MILLIONS)
    • Cancer
    • Ophthalmic
    • Scanning
    • DENTAL
  • Table 46 GLOBAL MARKET FOR PROBES IN THE DENTAL AREA, THROUGH 2010 ($ MILLIONS)
    • BLOOD BANKS
  • Table 47 GLOBAL MARKET FOR PROBES IN BLOOD BANKS, THROUGH 2010 ($ MILLIONS)
    • Types of Tests
    • FOOD TESTING
  • Table 48 GLOBAL MARKET FOR PROBES IN FOOD TESTING, THROUGH 2010 ($ MILLIONS)
    • RESEARCH LABORATORIES
  • Table 49 GLOBAL MARKET FOR PROBES IN RESEARCH LABORATORIES, THROUGH 2010 ($ MILLIONS)
    • Types of Tests
    • FORENSIC AND PATERNITY MARKETS
  • Table 50 MARKET FOR PROBES IN FORENSIC AND PATERNITY, THROUGH 2010 ($ MILLIONS)
  • Table 51 GLOBAL MARKET FOR PROBES IN FORENSIC AND PATERNITY, THROUGH 2010 ($ MILLIONS)
    • Forensics
      • Types of Tests
    • Paternity
      • Types of Tests
    • ENVIRONMENTAL TESTING
  • Table 52 MARKET FOR PROBES IN ENVIRONMENTAL TESTING, THROUGH 2010 ($ MILLIONS)
  • Table 53 GLOBAL MARKET FOR PROBES IN ENVIRONMENTAL TESTING, THROUGH 2010 ($ MILLIONS)
    • Bioterrorism
      • Bioterrorism (Continued)
• MARKET FOR PROBES-BY MATERIALS
  • FLUORESCENT COMPOUNDS
    • REQUIREMENTS FOR FLUORESCENT COMPOUNDS
    • APPLICATIONS OF FLUORESCENCE IMMUNOASSAY
    • FEATURES
      • Nucleic Acid Labeling
      • Protein Labeling
    • COMMONLY USED FLUOROCOMPOUNDS
  • Table 54 APPLICATIONS OF SPECIFIC FLUORESCENT COMPOUNDS
  • Table 54 (CONTINUED)
  • Table 55 MARKET FOR FLUORESCENT COMPOUNDS BY MATERIAL TYPES, THROUGH 2010 ($ MILLIONS)
    • Technology Development
  • Table 56 MARKETS OF FLUORESCENT COMPOUNDS BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
  • Figure 5 MARKETS OF FLUORESCENT COMPOUNDS BY APPLICATION SECTORS, 2003-2010 ($ MILLIONS)
    • RADIOACTIVE COMPOUNDS
  • Table 57 MARKET FOR RADIOACTIVE COMPOUNDS BY MATERIAL TYPES, THROUGH 2010 ($ MILLIONS)
    • RADIOACTIVE COMPOUNDS (CONTINUED)
  • Table 58 RADIOPHARMACEUTICALS CURRENTLY USED
  • Table 58 (CONTINUED)
  • Table 58 (CONTINUED)
  • Table 59 MARKETS FOR RADIOACTIVE COMPOUNDS BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
  • Figure 6 MARKETS FOR RADIOACTIVE COMPOUNDS BY APPLICATION SECTORS, 2003-2010 ($ MILLIONS)
    • CHEMILUMINESCENT COMPOUNDS
  • Table 60 TYPES OF CHEMILUMINESCENT ASSAY
  • Table 61 TYPES OF LUMINESCENT REACTIONS
    • APPLICATIONS OF CHEMILUMINESCENT COMPOUNDS
    • FACTORS IN CHOOSING A DETECTION REACTION
  • Table 62 MARKET FOR CHEMILUMINESCENT COMPOUNDS BY MATERIAL TYPES, THROUGH 2010 ($ MILLIONS)
  • Table 63 APPLICATIONS OF SELECTED CHEMILUMINESCENT COMPOUNDS
  • Table 64 MARKETS OF CHEMILUMINESCENT COMPOUNDS BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
  • Figure 7 MARKETS OF CHEMILUMINESCENT COMPOUNDS BY APPLICATION SECTORS, 2003-2010 ($ MILLIONS)
    • ENZYME/ENZYME SUBSTRATE
  • Table 65 MARKET FOR ENZYMES AND THEIR SUBSTRATES BY TYPE, THROUGH 2010 ($ MILLIONS)
  • Table 66 SELECTED ENZYME IMMUNOASSAY APPLICATIONS
  • Table 66 (CONTINUED)
  • Table 66 (CONTINUED)
  • Table 66 (CONTINUED)
  • Table 66 (CONTINUED)
  • Table 67 MARKETS FOR ENZYMES AND THEIR SUBSTRATES BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
  • Figure 8 MARKETS FOR ENZYMES AND THEIR SUBSTRATES BY APPLICATION SECTORS, 2003-2010 ($ MILLIONS)
    • GENE PROBES
  • Table 68 MARKET FOR GENE PROBES, THROUGH 2010 ($ MILLIONS)
  • Table 69 MARKETS FOR GENE PROBES BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
  • Figure 9 MARKETS FOR GENE PROBES BY APPLICATION SECTORS, 2003- 2010 ($ MILLIONS)
• REGULATIONS AFFECTING THE INDUSTRY
  • REGULATIONS AFFECTING RADIOACTIVE MATERIALS
  • Table 70 HISTORICAL TIMELINE OF REGULATIONS AFFECTING THE HANDLING OF RADIOISOTOPES IN THE U.S.
  • Table 70 (CONTINUED)
    • NUCLEAR REGULATORY COMMISSION (NRC) REGULATIONS
    • PRESENT RULES AND REGULATIONS
    • SAFETY STANDARDS
    • MEDICAL USE POLICY STATEMENT
    • ADVISORY COMMITTEE
  • Table 71 HIGHLIGHTS OF DEVELOPMENTS IN NRC REGULATIONS
    • REGULATIONS RELATING TO STORAGE OF RADIO ISOTOPES
    • SINK DISPOSAL
    • EXEMPTION TO SMALL QUANTITY ISOTOPES
    • EUROPEAN REGULATIONS ON WASTE DISPOSAL
    • PERMITS FOR THE IMPORT OF MEDICAL RADIOISOTOPES IN AUSTRALIA
      • PERMITS FOR THE IMPORT OF MEDICAL�ECONTINUED)
• GLOBAL HEALTHCARE AND INDUSTRY TRENDS
  • WORLD POPULATION AND DISEASE PROFILE
    • WORLD POPULATION AND GROWTH RATE
  • DISEASE PROFILE
    • KEY DETERMINANTS OF HEALTH
      • Key Determinants of Health (Continued)
      • Infectious Diseases
    • PATIENT CARE
  • Table 72 HOSPITAL BED STATISTICS FOR SELECTED COUNTRIES, 2004
    • DRIVING FACTORS OF TESTING IN DEVELOPING COUNTRIES
    • DRIVING FACTORS IN DEVELOPED COUNTRIES
    • CONSTRAINTS FOR GROWTH
    • THE STAKEHOLDERS
    • TECHNOLOGY FACTORS
      • ULTRATRACE
    • FACTORS INFLUENCING GROWTH
      • EXTENT OF UTILIZATION OF IVD PROCEDURES
    • GROWTH IN CONSUMPTION
    • PATTERN OF USE
    • HALF LIFE AND LIMITED AVAILABILITY IN SOME COUNTRIES
    • ENVIRONMENTAL ISSUES
      • OPTIONS FOR MINIMIZING RADIOACTIVE WASTE DISPOSAL PROBLEMS
    • COST ISSUES
    • SUBSTITUTION FOR RADIOISOTOPES
      • FUTURE FOR RADIOACTIVE PROBES
    • FUTURE FOR CHEMILUMINESCENT PROBES
    • FUTURE FOR ENZYME-BASED ASSAYS
    • FUTURE FOR FLUORESCENT PROBES
    • FUTURE FOR GENE PROBES
• PROBES-TECHNOLOGY AND PATENTS
  • FLUORESCENT COMPOUNDS
    • ELECTRONIC ARRAY DETECTORS
    • ASSAY SENSITIVITY AND TAGGING METHODS
    • SIMULTANEOUS ANALYSIS OF MULTIPLE SAMPLES FOR MULTIPLE ANALYTES
    • DIFFUSION IMMUNOASSAY (DIA)
    • STOPPED-FLOW FLUORESCENCE POLARIZATION IMMUNOASSAY
    • THE USE OF FLUORESCENCE POLARIZATION ASSAYS FOR THE DETECTION OF INFECTIOUS DISEASES
    • TISSUE AUTO FLUORESCENCE
  • CHEMILUMINESCENT COMPOUNDS
    • ASSAY SENSITIVITY AND TAGGING METHODS
    • BIOLUMINESCENT TAGS
    • CK-MB TEST
  • RADIOACTIVE COMPOUNDS
    • DIAGNOSIS OF INFECTIOUS AND INFLAMMATORY DISEASE
  • Table 73 DEVELOPMENTS IN RADIOLABELED COMPOUNDS
    • RADIOLABELED PEPTIDES FOR DIAGNOSIS AND THERAPY
    • USE OF LOW RADIATION DOSE
    • ENZYMES/ENZYME SUBSTRATES
      • DIAGNOSIS OF CEREBRAL ASPERGILLOSIS
      • NUCLEIC ACID MODIFYING ENZYMES
      • DIAGNOSIS OF RENAL DISORDERS
      • THE DIAGNOSIS OF TRYPANOSOMOSIS IN ANIMALS
      • DIAGNOSIS OF ECTOPIC PREGNANCY
    • IMMUNOASSAYS
      • MARKERS FOR RISK STUDY
      • DEVELOPMENT OF MONOCLONAL ANTIBODIES
      • ASSAY SENSITIVITY AND TAGGING METHODS
      • MOLECULAR BIOLOGY TECHNIQUES
    • GENE PROBES
      • RECENT DEVELOPMENTS IN NUCLEIC ACID HYBRIDIZATION
      • REAL-TIME POLYMERASE CHAIN REACTION (PCR) TESTING
      • TIME RESOLVED FLUORESCENT (TRF) IMMUNOASSAY TESTING
      • DIAGNOSIS OF MYOCARDIAL INFARCTION
      • TOOLS FOR REAGENT IMMOBILIZATION
        • Beads
        • Dots
        • Paramagnetic Particles
        • Tools for Sample Collection
        • Matrices for Test Development
        • Interferences in Immunoassays
        • Demand for Early Risk and Disease Detection
        • Machinery and Platforms
    • PATENT ANALYSIS
  • Table 74 PATENT ANALYSIS FOR SELECTED ORGANIZATIONS
    • DESCRIPTION OF SOME REPRESENTATIVE PATENTS
      • New Imaging Agent for CNS Disorders
        • Fluorobutenyl Tropanes for Mapping Transporter Sites
        • Halogenated Pyrroloisoquinolines for Mapping Serotonin Transporter Sites
      • Detection of Prostrate Cancer
        • Diagnosis and Monitoring of Prostate Cancer Patients by Measurement of Serum
      • Detection of Neurological Diseases
        • Method of Detecting Axonally-Derived Protein Tau in Patients With Traumatic CNS Injury
        • Method of Analyzing Ataxia-Telangiectasia Protein
        • Detection of Transmissible Spongiform Encephalopathies (Tses)
      • Simultaneous Generation of Multiple Chemiluminescent Signals on Solid Supports
      • Monoclonal Anti-Human Breast Cancer Antibodies
      • Autonomous Ingestible Probe for Diagnosis and Therapy of Gastrointestinal Lesions Using Fluorescent Molecules
      • Biochip Devices for Genetic Analyses
        • New Biochip Methods and Devices That Reduce the Cost and Complexity of Performing Genetic Analyses.
        • Biochip Devices For Genetic Analyses (Continued)
• PROFILE OF MAJOR PLAYERS
  • MARKET SHARE OF MAJOR PLAYERS
  • Table 75 MARKET SHARE OF MAJOR PLAYERS IN MEDICAL DIAGNOSTICS
    • ABBOTT LABORATORIES
      • HIGHLIGHTS
      • PRODUCT RANGE
        • Immunoassay
  • Table 76 REPRESENTATIVE ASSAY PRODUCTS OF ABBOTT
    • ACTIVITIES
    • FACILITIES
    • COLLABORATION
  • Table 77 SOME IMPORTANT COLLABORATION EFFORTS AT ABBOTT
  • Table 77 (CONTINUED)
    • AMERSHAM BIOSCIENCES, USA
      • BACKGROUND DETAILS
      • PRODUCT RANGE
      • ACTIVITY
      • FACILITIES
        • Research and Development
        • Global Operations
    • BACHEM AG
      • GMP PRODUCTION SITES
      • MANUFACTURING CAPABILITIES
      • MAJOR MILESTONES FOR BACHEM
  • Table 78 MAJOR MILESTONES FOR BACHEM
    • ASSOCIATED UNITS
  • Table 79 BACHEM UNITS
  • Table 79 (CONTINUED)
    • PRODUCT RANGE
      • Sera and Antibody Products
      • ELISA Kits
      • Research Reagents
      • Custom Iodination 125i-Labelling
    • FACILITIES
    • COLLABORATIONS
  • Table 80 BACHEM COLLABORATIONS
  • Table 80 (CONTINUED)
    • BIOFX LABORATORIES
      • LOCATIONS
      • PRODUCT RANGE
        • Microwell Substrate
        • Membrane Substrate
        • Microwell ELISA - Peroxidase Enzyme Systems
      • OTHER DETAILS
        • New Chemiluminescent Product for Peroxidase Enzyme Systems
    • BIO-NUCLEONICS INC.
      • ACTIVITIES
      • COLLABORATION AND ALLIANCE PARTNER
        • Patents
    • BIO-RAD, USA
      • PRODUCT RANGE
    • BIOTIUM, USA
      • PRODUCT RANGE
        • Fluorescent Calcium Indicators and Related Products
        • Fluorescent Indicators (Chloride, Ph, Etc.)
          • Chloride Indicators
          • Ph Indicators
          • Zinc Indicators
          • Enzyme Indicator
      • ACTIVITIES
    • BIOVECTRA DCL, USA
      • PRODUCT RANGE
        • Enzymes
  • Table 81 PRODUCT RANGE AND APPLICATION OF BIOVECTRA DCL
    • ACTIVITIES
    • BIOZYME LABORATORIES
      • PRODUCT RANGE
    • CARBOMER INC.
      • ACTIVITIES
      • PRODUCT RANGE
        • Fluorescent Reagents
        • Fluorescent Glycans
    • DIAGNOSTIC CHEMICALS LIMITED, USA
      • PRODUCT RANGE
      • ACTIVITY
      • OTHER DETAILS
        • L3K Technology
          • Immunodiagnostics
    • DUTCH DIAGNOSTICS
      • PRODUCT RANGE
    • HYTEST LTD.
      • PRODUCT RANGE
  • Table 82 REPRESENTATIVE PRODUCTS OF HYTEST
  • Table 82 (CONTINUED)
    • INSTITUTE OF ISOTOPE CO. LTD., HUNGARY
      • ACTIVITY
      • PRODUCT RANGE
        • Radionuclides
        • Radiochemicals
      • FACILITIES
    • INTERNATIONAL MUREX TECHNOLOGIES CORPORATION /
    • MUREX DIAGNOSTICS CORP.
      • MANUFACTURING PLANTS
      • PRODUCT RANGE
      • MILESTONES
    • LUMIGEN, INC
      • PRODUCT RANGE
  • Table 83 REPRESENTATIVE PRODUCTS OF LUMIGEN
    • Lumigens LMO Technology
    • MDS NORDION
      • EXPERTISE
      • PRODUCT RANGE
      • ACTIVITY
      • FACILITIES
      • COLLABORATION
  • Table 84 REPRESENTATIVE COLLABORATION EFFORTS OF MDS
  • Table 84 (CONTINUED)
    • MORAVEK BIOCHEMICALS, USA
      • ACTIVITY
      • PRODUCT RANGE
    • PERKINELMER LIFE SCIENCE, INC.
      • ACTIVITY
      • PRODUCT RANGE
        • Fluorescein-12-Dutp
        • NEN Brand Fluorescent Nucleotide Analogs
    • RESEARCH PRODUCTS INTERNATIONAL CORP., USA
      • PRODUCT RANGE
    • SIGMA ALDRICH, USA
      • ACTIVITIES
  • Table 85 MILESTONES FOR SIGMA ALDRICH
    • PRODUCT RANGE
      • Enzymes
      • Fluorescent Labels
        • Amine Derivatives
    • THERATASE, PLC
      • BACKGROUND DETAILS
      • PRODUCT RANGE
      • COLLABORATION
    • TOYOBO ENZYMES
      • FACILITIES
      • PRODUCT RANGE
  • Table 86 REPRESENTATIVE PRODUCTS OF TOYOBO
    • VECTOR LABS
      • PRODUCT RANGE
  • Table 87 REPRESENTATIVE PRODUCTS OF VECTOR LABS
  • Table 87 (CONTINUED)
    • ZYMED LABORATORIES, INC., USA
      • PRODUCT RANGE
        • Other Products
• LIST OF TABLES
• Summary Table:
• Table 1 IMMUNOASSAYS: HISTORICAL TIMELINE
• Table 2 GENE PROBES: HISTORICAL TIMELINE
• Table 3 RADIOACTIVE COMPOUNDS: HISTORICAL TIMELINE
• Table 4 COMMONLY USED RADIOACTIVE ISOTOPES
• Table 5 RADIONUCLIDES FOR DIAGNOSTIC IMAGING
• Table 6 RADIONUCLIDES: POSITRON EMITTERS
• Table 7 USE OF RADIOACTIVE PROBES: THYROID IMAGING
• Table 8 USE OF RADIOACTIVE PROBES: AUTORADIOGRAPHY
• Table 9 USE OF RADIOACTIVE PROBES: IN DIAGNOSIS AND THERAPY
• Table 10 USE OF RADIOACTIVE PROBES: RADIOCARDIOGRAPHY
• Table 11 USE OF RADIOACTIVE PROBES: TUMOR IMAGING
• Table 12 USE OF RADIOACTIVE PROBES: CANCER TREATMENT
• Table 13 USE OF RADIOACTIVE PROBES: DETERMINATION OF BLOOD CELL SURVIVAL TIME
• Table 14 USE OF RADIOACTIVE PROBES: DETERMINATION OF CIRCULATION RED CELL MASS/PLASMA VOLUME
• Table 15 USE OF RADIOACTIVE PROBES: DETERMINATION OF BLOOD FLOW
• Table 16 USE OF RADIOACTIVE PROBES: STOMACH IMAGING
• Table 17 USE OF RADIOACTIVE PROBES: EXCRETION STUDY
• Table 18 USE OF RADIOACTIVE PROBES: TREATMENT OF LEUKEMIAS
• Table 19 USE OF RADIOACTIVE PROBES: STUDY OF GASTROINTESTINAL PROTEIN LOSS
• Table 20 USE OF RADIOACTIVE PROBES: SCANNING LUNGS/BRAIN
• Table 21 USE OF RADIOACTIVE PROBES: MYOCARDIAL STUDIES
• Table 22 USE OF RADIOACTIVE PROBES: HEART IMAGING
• Table 23 USE OF RADIOACTIVE PROBES: BRAIN IMAGING
• Table 24 USE OF RADIOACTIVE PROBES: BRAIN PERFUSION IMAGING
• Table 25 USE OF RADIOACTIVE PROBES: BONE IMAGING
• Table 26 USE OF RADIOACTIVE PROBES: LUNG IMAGING
• Table 27 USE OF RADIOACTIVE PROBES: RENAL IMAGING
• Table 28 USE OF RADIOACTIVE PROBES: MALIGNANT AND INFLAMMATORY REGIONS
• Table 29 COMMONLY USED TYPE OF EIAS
• Table 30 COMMONLY USED ENZYMES IN EIAS
• Table 31 APPLICATIONS OF ENZYMES IN IMMUNOASSAY
• Table 32 COMMONLY USED FLUOROPHORES IN FIA
• Table 33 FLUOROPHORES AND THEIR APPLICATIONS
• Table 34 COMMONLY USED CHEMILUMINESCENT COMPOUNDS
• Table 35 GLOBAL MARKET FOR PROBES IN IMMUNOASSAYS BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
• Table 36 GLOBAL MARKET BY MATERIALS FOR PROBES IN IMMUNOASSAYS, THROUGH 2010 ($ MILLIONS)
• Table 37 REGIONAL SHARE OF THE MARKET FOR PROBES IN IMMUNOASSAYS, THROUGH 2010 ($ MILLIONS)
• Table 38 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
• Table 39 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS BY REGION, THROUGH 2010 ($ MILLIONS)
• Table 40 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS BY REAGENTS, THROUGH 2010 ($ MILLIONS)
• Table 41 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS MEDICAL LABS, THROUGH 2010 ($ MILLIONS)
• Table 42 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS HOSPITAL TESTING, THROUGH 2010 ($ MILLIONS)
• Table 43 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS DOCTORS OFFICE, THROUGH 2010 ($ MILLIONS)
• Table 44 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS HOME TESTING, THROUGH 2010 ($ MILLIONS)
• Table 45 GLOBAL MARKET FOR PROBES FOR IN VIVO DIAGNOSTICS, THROUGH 2010 ($ MILLIONS)
• Table 46 GLOBAL MARKET FOR PROBES IN THE DENTAL AREA, THROUGH 2010 ($ MILLIONS)
• Table 47 GLOBAL MARKET FOR PROBES IN BLOOD BANKS, THROUGH 2010 ($ MILLIONS)
• Table 48 GLOBAL MARKET FOR PROBES IN FOOD TESTING, THROUGH 2010 ($ MILLIONS)
• Table 49 GLOBAL MARKET FOR PROBES IN RESEARCH LABORATORIES, THROUGH 2010 ($ MILLIONS)
• Table 50 MARKET FOR PROBES IN FORENSIC AND PATERNITY, THROUGH 2010 ($ MILLIONS)
• Table 51 GLOBAL MARKET FOR PROBES IN FORENSIC AND PATERNITY, THROUGH 2010 ($ MILLIONS)
• Table 52 MARKET FOR PROBES IN ENVIRONMENTAL TESTING, THROUGH 2010 ($ MILLIONS)
• Table 53 GLOBAL MARKET FOR PROBES IN ENVIRONMENTAL TESTING, THROUGH 2010 ($ MILLIONS)
• Table 54 APPLICATIONS OF SPECIFIC FLUORESCENT COMPOUNDS
• Table 55 MARKET FOR FLUORESCENT COMPOUNDS BY MATERIAL TYPES, THROUGH 2010 ($ MILLIONS)
• Table 56 MARKETS OF FLUORESCENT COMPOUNDS BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
• Table 57 MARKET FOR RADIOACTIVE COMPOUNDS BY MATERIAL TYPES, THROUGH 2010 ($ MILLIONS)
• Table 58 RADIOPHARMACEUTICALS CURRENTLY USED
• Table 59 MARKETS FOR RADIOACTIVE COMPOUNDS BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
• Table 60 TYPES OF CHEMILUMINESCENT ASSAY
• Table 61 TYPES OF LUMINESCENT REACTIONS
• Table 62 MARKET FOR CHEMILUMINESCENT COMPOUNDS BY MATERIAL TYPES, THROUGH 2010 ($ MILLIONS)
• Table 63 APPLICATIONS OF SELECTED CHEMILUMINESCENT COMPOUNDS
• Table 64 MARKETS OF CHEMILUMINESCENT COMPOUNDS BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
• Table 65 MARKET FOR ENZYMES AND THEIR SUBSTRATES BY TYPE, THROUGH 2010 ($ MILLIONS)
• Table 66 SELECTED ENZYME IMMUNOASSAY APPLICATIONS
• Table 67 MARKETS FOR ENZYMES AND THEIR SUBSTRATES BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
• Table 68 MARKET FOR GENE PROBES, THROUGH 2010 ($ MILLIONS)
• Table 69 MARKETS FOR GENE PROBES BY APPLICATION SECTORS, THROUGH 2010 ($ MILLIONS)
• Table 70 HISTORICAL TIMELINE OF REGULATIONS AFFECTING THE HANDLING OF RADIOISOTOPES IN THE U.S.
• Table 71 HIGHLIGHTS OF DEVELOPMENTS IN NRC REGULATIONS
• Table 72 HOSPITAL BED STATISTICS FOR SELECTED COUNTRIES, 2004
• Table 73 DEVELOPMENTS IN RADIOLABELED COMPOUNDS
• Table 74 PATENT ANALYSIS FOR SELECTED ORGANIZATIONS
• Table 75 MARKET SHARE OF MAJOR PLAYERS IN MEDICAL DIAGNOSTICS
• Table 76 REPRESENTATIVE ASSAY PRODUCTS OF ABBOTT
• Table 77 SOME IMPORTANT COLLABORATION EFFORTS AT ABBOTT
• Table 78 MAJOR MILESTONES FOR BACHEM
• Table 79 BACHEM UNITS
• Table 80 BACHEM COLLABORATIONS
• Table 81 PRODUCT RANGE AND APPLICATION OF BIOVECTRA DCL
• Table 82 REPRESENTATIVE PRODUCTS OF HYTEST
• Table 83 REPRESENTATIVE PRODUCTS OF LUMIGEN
• Table 84 REPRESENTATIVE COLLABORATION EFFORTS OF MDS
• Table 85 MILESTONES FOR SIGMA ALDRICH
• Table 86 REPRESENTATIVE PRODUCTS OF TOYOBO
• Table 87 REPRESENTATIVE PRODUCTS OF VECTOR LABS
• LIST OF FIGURES
• Summary Figure:
• Figure 1 GLOBAL MARKET BY MATERIALS FOR PROBES IN IMMUNOASSAYS, 2003-2010 ($ MILLIONS)
• Figure 2 REGIONAL SHARE OF MARKETS FOR PROBES IN IMMUNOASSAYS, 2005 (%)
• Figure 3 GLOBAL MARKET FOR PROBES FOR IN VITRO DIAGNOSTICS BY APPLICATION SECTORS, 2003-2010 ($ MILLIONS)
• Figure 4 GLOBAL MARKET FOR PROBES FOR IN VIVO DIAGNOSTICS, 2003-2010 ($ MILLIONS)
• Figure 5 MARKETS OF FLUORESCENT COMPOUNDS BY APPLICATION SECTORS, 2003-2010 ($ MILLIONS)
• Figure 6 MARKETS FOR RADIOACTIVE COMPOUNDS BY APPLICATION SECTORS, 2003-2010 ($ MILLIONS)
• Figure 7 MARKETS OF CHEMILUMINESCENT COMPOUNDS BY APPLICATION SECTORS, 2003-2010 ($ MILLIONS)
• Figure 8 MARKETS FOR ENZYMES AND THEIR SUBSTRATES BY APPLICATION SECTORS, 2003-2010 ($ MILLIONS)
• Figure 9 MARKETS FOR GENE PROBES BY APPLICATION SECTORS, 2003- 2010 ($ MILLIONS)